GlassScriptPhysician profile
Hadir Mohamed
NPI 1992158141
$3,433.06
in general payments reported to CMS, 2019-2025
33 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.02 · 2023: $831 · 2024: $1,015 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,306.57 |
| Education | $101.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $635.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $363.23 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $355.78 | 2022-2025 | Minimed 780g |
| Abbott Laboratories | $264.92 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $261.63 | 2023-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $210.49 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $170.86 | 2023-2025 | |
| Abbvie INC. | $156.96 | 2023-2025 | |
| Insulet Corporation | $144.88 | 2023-2025 | Omnipod |
| Dexcom, INC. | $88.64 | 2023-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $83.21 | 2024-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $72.67 | 2023 | Dificid, Pifeltro, Delstrigo |
| Stryker Corporation | $60.78 | 2025 | Everest Spinal System |
| Mannkind Corporation | $59.83 | 2025 | |
| Tandem Diabetes Care, INC. | $57.84 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $56.95 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $52.83 | 2025 | Yorvipath |
| Corcept Therapeutics | $36.17 | 2025 | Korlym |
| Ibsa Pharma INC. | $33.84 | 2024-2025 | Tirosint, Licart, Flector |
| Astrazeneca Pharmaceuticals LP | $32.88 | 2023 | Farxiga |
| Cequr Corporation | $28.96 | 2023-2025 | Cequr Simplicity |
| Astellas Pharma US INC | $22.77 | 2024 | Veozah |
| Integra Lifesciences Corporation | $21.95 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Ucb, INC. | $18.72 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.93 | 2023 | Jardiance |
| Vivus LLC | $17.00 | 2024 | Pancreaze |
| Radius Health, INC. | $16.87 | 2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $15.80 | 2023 | Strensiq |
| Amphastar Pharmaceuticals, INC. | $15.12 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.94 | 2024 | Nuzyra |
| Resmed Corp | $14.78 | 2023 | |
| Aimmune Therapeutics, INC. | $14.23 | 2024 | |
| Tolmar, INC. | $14.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadir Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.